Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Antex Biologics successfully completes phase I study of Helicobacter vaccine

Jan. 29, 1999

Yoshitomi's new immunosuppressive agents for arthritis, autoimmune diseases and transplant rejection

Jan. 27, 1999

Another significant market introduction for basiliximab

Jan. 25, 1999

Glaxo Wellcome and PowderJect expand DNA vaccine collaboration

Jan. 25, 1999

Alpha-Beta Technology discontinues phase III trial of Betafectin

Jan. 25, 1999

Cel-Sci and University of Maryland receive award for TB vaccine development

Jan. 22, 1999

Terprenin: novel immunosuppressant and antiallergic substance under evaluation at Shionogi

Jan. 22, 1999

Antex Biologics receives milestone payment from Pasteur Merieux Connaught

Jan. 21, 1999

FDA committee does not recommend approval of Prograf for GVHD

Jan. 21, 1999

Global FluMist collaboration announced by Aviron and Wyeth Lederle Vaccines

Jan. 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...